- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Milken Institute's Sarah Wells Kocsis Highlights Key Findings of Her Research on CKD
Sarah Wells Kocsis, MBA, is co-author of the Milken Institute report, “Chronic Kidney Disease: Finding a Path to Prevention, Earlier Detection, and Management.” She spoke to The American Journal of Managed Care® about the findings of the report and how they can be incorporated into care for patients with chronic kidney disease (CKD).
Sarah Wells Kocsis, MBA, director of the Center for Public Health at the Milken Institute, talks about the key findings of her recently authored report, “Chronic Kidney Disease: Finding a Path to Prevention, Earlier Detection, and Management.”
Transcript
What are the biggest takeaways of your research?
Chronic kidney disease [CKD] is a huge public health problem. It's intricately tied to health equity and social determinants of health. So tackling CKD is going to require a major shift in our mindset and the approach. Roughly 1 in 7 adults have chronic kidney disease, and 9 out of 10 of them don't even know that they have it, so we really need to listen to what the research is telling us. And what it's telling us is that we really need to focus right now on root causes, and these causes are structural, social, and health related. That's going to require practical, scalable, equitable solutions aimed at both detecting and managing the condition upstream at earlier stages and focusing on reducing the burden of this debilitating disease.
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study
April 17th 2024Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Read More
